MA44154A - Procédé de traitement ou d'amélioration de troubles métaboliques à l'aide de protéines de liaison au récepteur du peptide inhibiteur gastrique (gipr) en association avec des agonistes du glp-1 - Google Patents

Procédé de traitement ou d'amélioration de troubles métaboliques à l'aide de protéines de liaison au récepteur du peptide inhibiteur gastrique (gipr) en association avec des agonistes du glp-1

Info

Publication number
MA44154A
MA44154A MA044154A MA44154A MA44154A MA 44154 A MA44154 A MA 44154A MA 044154 A MA044154 A MA 044154A MA 44154 A MA44154 A MA 44154A MA 44154 A MA44154 A MA 44154A
Authority
MA
Morocco
Prior art keywords
gipr
glp
amelioration
agonists
association
Prior art date
Application number
MA044154A
Other languages
English (en)
Inventor
Neeraj Agrawal
Darren L Bates
Brandon C P Clavette
Ian N Foltz
Shu-Yin Ho
Renee Komorowski
David J Lloyd
Xiaoshan Min
Christopher Murawsky
Donghui Shi
Jr Glenn N Sivits
Murielle M Veniant-Ellison
Jinghong Wang
Zhulun Wang
Junming Yie
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA44154A publication Critical patent/MA44154A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MA044154A 2015-12-23 2016-12-21 Procédé de traitement ou d'amélioration de troubles métaboliques à l'aide de protéines de liaison au récepteur du peptide inhibiteur gastrique (gipr) en association avec des agonistes du glp-1 MA44154A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562387486P 2015-12-23 2015-12-23
US201662337799P 2016-05-17 2016-05-17
US201662420415P 2016-11-10 2016-11-10

Publications (1)

Publication Number Publication Date
MA44154A true MA44154A (fr) 2018-10-31

Family

ID=57956369

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044154A MA44154A (fr) 2015-12-23 2016-12-21 Procédé de traitement ou d'amélioration de troubles métaboliques à l'aide de protéines de liaison au récepteur du peptide inhibiteur gastrique (gipr) en association avec des agonistes du glp-1

Country Status (25)

Country Link
US (4) US10294303B2 (fr)
EP (1) EP3394104A2 (fr)
JP (4) JP6948330B2 (fr)
KR (2) KR20250121615A (fr)
CN (2) CN109715662B (fr)
AU (2) AU2016378739A1 (fr)
CA (2) CA3009650A1 (fr)
CL (2) CL2018001695A1 (fr)
CO (1) CO2018007582A2 (fr)
CR (1) CR20180378A (fr)
EA (1) EA201891323A1 (fr)
IL (2) IL296682B2 (fr)
MA (1) MA44154A (fr)
MX (2) MX395677B (fr)
MY (1) MY197023A (fr)
NZ (1) NZ743474A (fr)
PE (1) PE20181327A1 (fr)
PH (1) PH12018501322A1 (fr)
SG (1) SG11201805255TA (fr)
TN (1) TN2018000225A1 (fr)
TW (4) TWI734722B (fr)
UA (1) UA127495C2 (fr)
UY (1) UY37049A (fr)
WO (1) WO2017112824A2 (fr)
ZA (2) ZA201803979B (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6936221B2 (ja) 2015-11-02 2021-09-15 ファイブ プライム セラピューティクス， インコーポレイテッド Ｃｄ８０細胞外ドメインポリペプチドと、がん治療でのそれらの使用
CR20180378A (es) 2015-12-23 2018-12-06 Amgen Inc Método para tratar o mejorar trastornos metabólicos con proteínas de unión para el receptor peptídico inhibidor gástrico (gipr) en combinación con agosnistas de glp-1
MX2019003727A (es) * 2016-09-29 2019-08-05 Amgen Inc Proteinas de union a antigeno de baja viscosidad y metodos de prepararlas.
KR102781241B1 (ko) 2017-01-17 2025-03-14 암젠 인크 위 저해 펩타이드 수용체(gipr)에 대한 길항제에 접합된 glp-1 수용체 작용제를 사용하여 대사 장애를 치료 또는 개선하는 방법
MX2019013919A (es) * 2017-06-20 2020-01-21 Amgen Inc Metodo para tratar o mejorar trastornos metabolicos con proteinas de union para el receptor peptidico inhibidor gastrico (gipr) en combinacion con agonistas de glp-1.
JP7250706B2 (ja) * 2017-06-21 2023-04-03 アムジエン・インコーポレーテツド 胃抑制ペプチド受容体（ｇｉｐｒ）に対するアンタゴニスト結合タンパク質／ｇｌｐ－１受容体アゴニスト融合タンパク質を使用した代謝障害の治療又は寛解方法
FI3661562T3 (fi) * 2017-08-04 2024-12-09 Amgen Inc Cys-mab:ien konjugointimenetelmä
IL322969A (en) 2017-10-12 2025-10-01 Novo Nordisk As Semaglutide in medical therapy
CN117003874A (zh) * 2018-03-20 2023-11-07 鸿运华宁（杭州）生物医药有限公司 Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
EP3934679A1 (fr) 2019-03-08 2022-01-12 Amgen Inc. Polythérapie par facteur de différenciation de croissance 15
CN112521501A (zh) * 2019-09-18 2021-03-19 鸿运华宁（杭州）生物医药有限公司 Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
CN114423475B (zh) * 2019-09-30 2024-03-26 美国安进公司 药物递送装置和用于递送药物的方法
JP2022549687A (ja) * 2019-09-30 2022-11-28 アムジエン・インコーポレーテツド 薬物送達デバイス
WO2021067655A1 (fr) 2019-10-04 2021-04-08 Amgen Inc. Utilisation de gdf15 pour le traitement d'un syndrome cardiométabolique et d'autres affections
US20220403038A1 (en) * 2019-11-07 2022-12-22 Amgen Inc. Method of treating or ameliorating cushing's syndrome using binding proteins for gastric inhibitory peptide receptor (gipr)
WO2021202013A1 (fr) * 2020-03-30 2021-10-07 Crystal Bioscience Inc. Anticorps anti-gipr et ses procédés d'utilisation
CA3221655A1 (fr) * 2021-06-09 2022-12-15 Swiftnovo Therapeutics Inc. Agents therapeutiques et methodes de traitement ou de reduction de troubles metaboliques
JP2025531814A (ja) 2022-09-08 2025-09-25 ジーマックス バイオファーム エルエルシー Ｇｉｐｒ抗体、ｆｇｆ２１との融合タンパク質、その医薬組成物及びその使用
CN120019167A (zh) * 2022-10-12 2025-05-16 首尔大学医院 利用gipr标记物的用于预测磺酰脲类依赖性的组合物及其预测方法
KR102679905B1 (ko) * 2022-10-12 2024-07-02 서울대학교병원 Gipr 마커를 이용한 설폰요소제 의존성 예측용 조성물 및 그 예측 방법
EP4613768A1 (fr) 2022-11-02 2025-09-10 Suzhou Alphamab Co., Ltd Protéine de liaison au gipr et son utilisation
WO2024209050A1 (fr) 2023-04-05 2024-10-10 Antag Therapeutics Aps Modulateurs de l'activité du gip et intolérance orthostatique
EP4455159A1 (fr) * 2023-04-25 2024-10-30 3B Pharmaceuticals GmbH Ligands de récepteur de peptide inhibiteur gastrique avec modificateur de biodistribution
US20250163168A1 (en) 2023-11-17 2025-05-22 Pfizer Inc. Novel antibodies and antibody conjugates for the treatment of metabolic disorders
TW202539633A (zh) * 2024-02-01 2025-10-16 美商輝瑞股份有限公司 葡萄糖依賴性促胰島素多肽受體拮抗劑及其用途
WO2025199030A1 (fr) 2024-03-18 2025-09-25 Amgen Inc. Agonistes du récepteur glp-1 et leur utilisation médicale
WO2025226506A1 (fr) * 2024-04-23 2025-10-30 Protagonist Therapeutics, Inc. Composés mono- et doubles agonistes de glp1r et gipr humains pour l'obésité et t2dm
US20260121272A1 (en) * 2024-10-31 2026-04-30 Allegro Microsystems, Llc Multi-channel isolation transformer and gate driver structures
WO2026093993A1 (fr) 2024-11-01 2026-05-07 Janssen Biotech, Inc. Procédés et systèmes pour ciblage métabolique et cellulaire multispécifiques amélioré

Family Cites Families (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
WO1988001649A1 (fr) 1986-09-02 1988-03-10 Genex Corporation Molecules de liaison de chaines de polypeptide simples
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990005183A1 (fr) 1988-10-31 1990-05-17 Immunex Corporation Recepteurs d'interleukine-4
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5683888A (en) 1989-07-22 1997-11-04 University Of Wales College Of Medicine Modified bioluminescent proteins and their use
US5292658A (en) 1989-12-29 1994-03-08 University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center Cloning and expressions of Renilla luciferase
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
WO1991018982A1 (fr) 1990-06-05 1991-12-12 Immunex Corporation Recepteurs de l'interleukine-1 de type ii
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
JP3126980B2 (ja) 1991-03-11 2001-01-22 ザ・ユニバーシテイ・オブ・ジヨージア・リサーチ・フアウンデーシヨン・インコーポレーテツド レニラ（ｒｅｎｉｌｌａ）ルシフェラーゼのクローニング及び発現
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
WO1992022646A1 (fr) 1991-06-14 1992-12-23 Dnx Corp. Procede d'utilisation de porcs transgeniques dans la production d'hemoglobine humaine
JPH06508880A (ja) 1991-07-08 1994-10-06 ユニバーシティ　オブ　マサチューセッツ　アット　アムハースト サーモトロピック液晶セグメント化ブロックコポリマー
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
AU694745B2 (en) 1993-09-10 1998-07-30 Trustees Of Columbia University In The City Of New York, The Uses of green fluorescent protein
WO1995021191A1 (fr) 1994-02-04 1995-08-10 William Ward Indicateur bioluminescent fonde sur l'expression d'un gene codant pour une proteine modifiee a fluorescence verte
US5777079A (en) 1994-11-10 1998-07-07 The Regents Of The University Of California Modified green fluorescent proteins
EP0822830B1 (fr) 1995-04-27 2008-04-02 Amgen Fremont Inc. Anticorps anti-IL-8 dérivés de xenosouris immunisées
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US5804387A (en) 1996-02-01 1998-09-08 The Board Of Trustees Of The Leland Stanford Junior University FACS-optimized mutants of the green fluorescent protein (GFP)
US5876995A (en) 1996-02-06 1999-03-02 Bryan; Bruce Bioluminescent novelty items
US5925558A (en) 1996-07-16 1999-07-20 The Regents Of The University Of California Assays for protein kinases using fluorescent protein substrates
DE69739172D1 (de) 1996-08-08 2009-01-29 Amylin Pharmaceuticals Inc Regulation gastrointestinaler beweglichkeit
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
US7091183B1 (en) 1996-12-03 2006-08-15 Boston Medical Center Corporation Specific antagonists for glucose-dependent insulinotropic polypeptide (GIP)
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
AU5518798A (en) 1996-12-03 1998-06-29 Trustees Of Boston University Specific antagonists for glucose-dependent insulinotropic polypeptide (gip)
WO1998026277A2 (fr) 1996-12-12 1998-06-18 Prolume, Ltd. Appareil permettant de detecter et d'identifier des agents infectieux et procede correspondant
PT1629849E (pt) 1997-01-07 2013-07-09 Amylin Pharmaceuticals Llc Composições farmacêuticas que compreendem exendinas e seus agonistas
CA2196496A1 (fr) 1997-01-31 1998-07-31 Stephen William Watson Michnick Epreuve de complementation de fragments de proteines pour la detection d'interactions entre proteines
US6753165B1 (en) 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
DK1019077T4 (da) 1997-08-08 2011-03-07 Amylin Pharmaceuticals Inc Hidtil ukendte exendinagonistforbindelser
US7157555B1 (en) 1997-08-08 2007-01-02 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
JP2003522721A (ja) 1997-11-14 2003-07-29 アミリン・ファーマシューティカルズ，インコーポレイテッド 新規なエキセンジンアゴニスト化合物
JP2001523688A (ja) 1997-11-14 2001-11-27 アミリン・ファーマシューティカルズ，インコーポレイテッド 新規エキセンジン・アゴニスト化合物
US7223725B1 (en) 1997-11-14 2007-05-29 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
US7220721B1 (en) 1997-11-14 2007-05-22 Amylin Pharmaceuticals, Inc. Exendin agonist peptides
US6703359B1 (en) 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
ATE366115T1 (de) 1998-02-13 2007-07-15 Amylin Pharmaceuticals Inc Inotropische und diuretische effekte von exendin und glp-1
AU765703B2 (en) 1998-03-27 2003-09-25 Bruce J. Bryan Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items
AU6294899A (en) 1998-10-07 2000-04-26 Medical College Of Georgia Research Institute, Inc. Glucose-dependent insulinotropic peptide for use as an osteotropic hormone
PL205713B1 (pl) 1998-12-07 2010-05-31 Sod Conseils Rech Applic Związki stanowiące analogi GLP-1, kompozycje farmaceutyczne zawierające takie związki oraz zastosowanie tych związków
CA2358107C (fr) 1998-12-22 2011-08-23 Eli Lilly And Company Formulation de longue conservation de peptide-1 de type glucagon
US20030087820A1 (en) 1999-01-14 2003-05-08 Young Andrew A. Novel exendin agonist formulations and methods of administration thereof
CN101181236A (zh) 1999-01-14 2008-05-21 安米林药品公司 新型exendin激动剂制剂及其给药方法
EP1658856B1 (fr) 1999-01-14 2010-03-17 Amylin Pharmaceuticals, Inc. Exendines destinés à la suppression du glucagon
US20050272652A1 (en) 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
DE60012721T4 (de) 1999-03-29 2010-09-09 Uutech Ltd., Coleraine Analoge des magensaft inhibierenden peptides und ihre verwendung für die behandlung von diabetes
US6506724B1 (en) 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
EP1246638B2 (fr) 2000-01-10 2014-07-30 Amylin Pharmaceuticals, Inc. Utilisation d'exendines et d'agonistes de ces dernieres pour traiter l'hypertriglyceridemie
HUP0204281A3 (en) 2000-01-27 2007-03-28 Lilly Co Eli Process for sulubilizing glucagon-like peptide 1 (glp-1) compounds
AU5675701A (en) 2000-05-16 2001-11-26 Sanwa Kagaku Kenkyusho Co Agents for preventing or ameliorating insulin resistance and/or obesity
IL158418A0 (en) 2001-04-19 2004-05-12 Scripps Research Inst In vivo incorporation of unnatural amino acids
US20050159379A1 (en) 2001-05-18 2005-07-21 Sirna Therapeutics, Inc RNA interference mediated inhibition of gastric inhibitory polypeptide (GIP) and gastric inhibitory polypeptide receptor (GIPR) gene expression using short interfering nucleic acid (siNA)
JP4566459B2 (ja) 2001-06-07 2010-10-20 株式会社日立製作所 表示装置
WO2003055914A2 (fr) * 2001-12-21 2003-07-10 7Tm Pharma A/S Recepteurs modifies pour la recherche de ligands therapeutiques
CN1332711C (zh) 2002-02-20 2007-08-22 埃米球科技有限公司 施用glp－1分子的方法
EP1506777A4 (fr) 2002-05-22 2007-07-18 Sanwa Kagaku Kenkyusho Co Medicament contre l'obesite a base de methylidene hydrazide
EP1515746A2 (fr) * 2002-06-11 2005-03-23 Eisai Co. Ltd Utilisation de composes ayant une activite gip dans le traitement de troubles associes a une perte anormale de cellules et/ou dans le traitement de l'obesite
CA2489323A1 (fr) 2002-06-15 2003-12-24 Enteromed, Inc. Prevention et traitement d'une steatose hepatique non alcoolique (nafld), par antagonisme du recepteur du polypeptide insulinotropique gluco-dependant (gip)
JP2006213598A (ja) 2003-03-19 2006-08-17 Sanwa Kagaku Kenkyusho Co Ltd ピラゾロピリミジン化合物及びその用途
JP4629047B2 (ja) 2003-06-12 2011-02-09 イーライ リリー アンド カンパニー Ｇｌｐ−１アナログ複合タンパク質
EP1663295A2 (fr) 2003-09-01 2006-06-07 Novo Nordisk A/S Formulations de peptides stables
US20060094652A1 (en) 2004-02-11 2006-05-04 Levy Odile E Hybrid polypeptides with selectable properties
US7456254B2 (en) 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
US7991890B2 (en) 2004-09-30 2011-08-02 Microsoft Corporation Game console communication with a device
AU2005298689A1 (en) 2004-10-25 2006-05-04 Cytos Biotechnology Ag Gastric inhibitory polypeptide (GIP) antigen arrays and uses thereof
PT1831252E (pt) 2004-12-22 2009-09-17 Lilly Co Eli Formulações de proteínas de fusão de análogos de glp-1
US20060275288A1 (en) 2005-01-20 2006-12-07 Grihalde Nelson D GLP-1 receptor agonist and allosteric modulator monoclonal antibodies and uses thereof
BRPI0606992A2 (pt) 2005-02-11 2009-07-28 Amylin Pharmaceuticals Inc análogo e polipeptìdeos hìbridos de gip com propriedades selecionáveis
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
EP1882044A1 (fr) 2005-05-11 2008-01-30 sanofi-aventis Utilisation du polymorphisme d'un promoteur gip
WO2006125763A1 (fr) 2005-05-25 2006-11-30 Novo Nordisk A/S Formulations de polypeptides stabilises
WO2007028633A2 (fr) * 2005-09-08 2007-03-15 Uutech Limited Traitement de l'obesite associee aux diabetes
EP2004238A2 (fr) 2006-03-21 2008-12-24 Amylin Pharmaceuticals, Inc. Conjugués inhibiteur de peptidase-peptide et procédés d'utilisation de ceux-ci
CA2657103A1 (fr) 2006-07-07 2008-01-10 The Texas A&M University System Derives atypiques de belactosine en tant qu'agents therapeutiques/sondes biologiques et leur synthese
EP2068910A2 (fr) 2006-08-04 2009-06-17 Amylin Pharmaceuticals, Inc. Utilisation d'exendines et d'agonistes d'exendines et d'agonistes du récepteur glp-1 pour modifier la dimension de particule et la composition de sous-classe de lipoprotéines
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
WO2008021560A2 (fr) 2006-08-17 2008-02-21 Amylin Pharmaceuticals, Inc. Analogue du gip et polypeptides hybrides possédant des propriétés sélectives
US20090098130A1 (en) 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
MX2009008241A (es) 2007-02-15 2009-10-08 Univ Indiana Res & Tech Corp Co-agonistas de receptor de glucagon/glp-1.
EP2195034A2 (fr) 2007-09-27 2010-06-16 Amylin Pharmaceuticals, Inc. Conjugués inhibiteurs de peptide/peptidase et leurs procédés de fabrication et d'utilisation
US20090144162A1 (en) 2007-11-29 2009-06-04 Neil Milne Transaction Security Method and Apparatus
GB0814068D0 (en) 2008-08-01 2008-09-10 Univ Ulster Active immunisation against GIP
KR20110043688A (ko) * 2008-08-07 2011-04-27 입센 파마 에스.에이.에스 포도당 의존적인 인슐린 분비 자극성 폴리펩타이드 유사체
CA2733006A1 (fr) 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Analogues de polypeptide insulinotrope glucose-dependant (gip) modifies a l'extremite n-terminale
EA020018B1 (ru) 2008-08-07 2014-08-29 Ипсен Фарма С.А.С. Процессированные аналоги глюкозозависимого инсулинотропного полипептида
WO2010016936A1 (fr) 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Compositions pharmaceutiques d'analogues de polypeptide insulinotrope glucose-dépendant
MX2011001031A (es) 2008-08-07 2011-04-26 Ipsen Pharma Sas Analogos de polipeptidos insulinotropicos dependientes de glucosa.
WO2011014680A2 (fr) 2009-07-31 2011-02-03 The Board Of Trustees Of The Leland Stanford Junior University Variantes du peptide inhibiteur gastrique et leurs utilisations
EP2528618A4 (fr) 2010-01-27 2015-05-27 Univ Indiana Res & Tech Corp Conjugués d'antagoniste du glucagon et d'agoniste du gip et compositions pour le traitement de troubles métaboliques et de l'obésité
CA2798273A1 (fr) * 2010-05-04 2011-11-10 Merrimack Pharmaceuticals, Inc. Anticorps contre le recepteur du facteur de croissance epidermique (egfr) et leurs utilisations
US9023986B2 (en) 2010-10-25 2015-05-05 Hoffmann-La Roche Inc. Glucose-dependent insulinotropic peptide analogs
WO2012088116A2 (fr) 2010-12-22 2012-06-28 Indiana University Research And Technology Corporation Analogues du glucagon présentant une activité de récepteur de gip
WO2012121302A1 (fr) 2011-03-08 2012-09-13 株式会社 三和化学研究所 Méthode d'analyse
US9453062B2 (en) 2011-06-10 2016-09-27 Beijing Hanmi Pharmaceutical Co., Ltd. Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof
CA2880929A1 (fr) 2012-09-07 2014-03-13 Sanofi Proteines de fusion pour traiter un syndrome metabolique
WO2015022420A1 (fr) 2013-08-16 2015-02-19 Medimmune Limited Agonistes doubles de récepteur de gip et glp-1 pour le traitement du diabète
WO2015081440A1 (fr) 2013-12-04 2015-06-11 Innovative Targeting Solutions Inc. Agonistes de récepteurs couplés aux protéines g et procédés associés
CN106068127B (zh) 2013-12-13 2020-06-19 诺和诺德保健股份有限公司 蛋白质的硫醚缀合方法
HUE067414T2 (hu) * 2013-12-17 2024-10-28 Mhs Care Innovation Llc Készítmények és eljárások zsírszövet felhalmozódásának kezelésére
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
AR104932A1 (es) 2015-06-22 2017-08-23 Lilly Co Eli Compuestos co-agonistas del glucagón y péptido-1 similar al glugacón (glp-1)
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
CR20180378A (es) 2015-12-23 2018-12-06 Amgen Inc Método para tratar o mejorar trastornos metabólicos con proteínas de unión para el receptor peptídico inhibidor gástrico (gipr) en combinación con agosnistas de glp-1
KR102781241B1 (ko) 2017-01-17 2025-03-14 암젠 인크 위 저해 펩타이드 수용체(gipr)에 대한 길항제에 접합된 glp-1 수용체 작용제를 사용하여 대사 장애를 치료 또는 개선하는 방법
MX2019013919A (es) 2017-06-20 2020-01-21 Amgen Inc Metodo para tratar o mejorar trastornos metabolicos con proteinas de union para el receptor peptidico inhibidor gastrico (gipr) en combinacion con agonistas de glp-1.
JP7250706B2 (ja) 2017-06-21 2023-04-03 アムジエン・インコーポレーテツド 胃抑制ペプチド受容体（ｇｉｐｒ）に対するアンタゴニスト結合タンパク質／ｇｌｐ－１受容体アゴニスト融合タンパク質を使用した代謝障害の治療又は寛解方法
FI3661562T3 (fi) * 2017-08-04 2024-12-09 Amgen Inc Cys-mab:ien konjugointimenetelmä
EP3934679A1 (fr) * 2019-03-08 2022-01-12 Amgen Inc. Polythérapie par facteur de différenciation de croissance 15

Also Published As

Publication number Publication date
TWI891060B (zh) 2025-07-21
NZ743474A (en) 2023-03-31
CL2020003237A1 (es) 2021-07-02
CN109715662A (zh) 2019-05-03
CL2018001695A1 (es) 2018-11-23
IL259940B (en) 2022-10-01
CR20180378A (es) 2018-12-06
TW202144430A (zh) 2021-12-01
JP2024001194A (ja) 2024-01-09
JP6948330B2 (ja) 2021-10-13
US10294303B2 (en) 2019-05-21
TWI734722B (zh) 2021-08-01
WO2017112824A3 (fr) 2017-08-10
US20220025059A1 (en) 2022-01-27
JP2021193135A (ja) 2021-12-23
TW202539736A (zh) 2025-10-16
AU2024200758A1 (en) 2024-05-02
US12252540B2 (en) 2025-03-18
IL259940B2 (en) 2023-02-01
IL259940A (en) 2018-07-31
KR102844773B1 (ko) 2025-08-13
IL296682A (en) 2022-11-01
US11046774B2 (en) 2021-06-29
MX2018007859A (es) 2018-11-09
JP2025124705A (ja) 2025-08-26
TWI818277B (zh) 2023-10-11
UY37049A (es) 2017-06-30
PH12018501322A1 (en) 2019-02-18
PE20181327A1 (es) 2018-08-20
MX395677B (es) 2025-03-25
KR20180108602A (ko) 2018-10-04
CO2018007582A2 (es) 2018-07-31
UA127495C2 (uk) 2023-09-13
ZA201803979B (en) 2021-07-28
EA201891323A1 (ru) 2019-02-28
NZ783798A (en) 2025-07-25
CA3009650A1 (fr) 2017-06-29
CN109715662B (zh) 2023-07-21
TW202400655A (zh) 2024-01-01
ZA201906059B (en) 2021-07-28
TW201731878A (zh) 2017-09-16
US20190276546A1 (en) 2019-09-12
WO2017112824A2 (fr) 2017-06-29
AU2016378739A1 (en) 2018-07-05
JP7686719B2 (ja) 2025-06-02
BR112018012833A2 (en) 2018-12-04
WO2017112824A8 (fr) 2018-08-09
TN2018000225A1 (en) 2019-10-04
EP3394104A2 (fr) 2018-10-31
US20250376529A1 (en) 2025-12-11
CA3223591A1 (fr) 2017-06-29
JP2019504032A (ja) 2019-02-14
KR20250121615A (ko) 2025-08-12
MX2022011277A (es) 2022-10-07
IL296682B2 (en) 2026-02-01
IL296682B1 (en) 2025-10-01
US20170275370A1 (en) 2017-09-28
MY197023A (en) 2023-05-22
CN117106085A (zh) 2023-11-24
SG11201805255TA (en) 2018-07-30

Similar Documents

Publication Publication Date Title
MA47314A (fr) Procédé de traitement ou d'amélioration de troubles métaboliques à l'aide d'agonistes du récepteur du glp-1 conjugués à des antagonistes du récepteur du peptide inhibiteur gastrique (gipr)
MA49460A (fr) Méthode de traitement ou de réduction de troubles métaboliques à l'aide de protéines de liaison au récepteur du peptide inhibiteur gastrique (gipr) en association avec des agonistes du glp-1
MA49459A (fr) Méthode de traitement ou d'amélioration des troubles métaboliques à l'aide de protéines de liaison antagonistes pour protéines de fusion agonistes du récepteur du peptide inhibiteur gastrique (gipr)/récepteur glp-1
ZA201906059B (en) Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
EP3515944A4 (fr) Procédés de traitement de troubles immunitaires à l'aide de protéines de liaison à pd-1
EP3341000A4 (fr) Systèmes et procédés pour le traitement d'une dysbiose à l'aide de populations bactériennes dérivées de fèces
EP3331527A4 (fr) Procédés de traitement de troubles du développement à l'aide de pipradrol
EP3423047A4 (fr) Compositions d'agonistes sélectifs du récepteur cb2 pour le traitement des troubles mentaux
EP3359074A4 (fr) Électroporation pour le traitement de l'obésité ou le diabète
EP3324973A4 (fr) Systèmes et procédés pour le traitement de l' il avec un photosensibilisateur
MA50763A (fr) Compositions d'acides aminés et méthodés de traitement de maladies et troubles musculaires
MA46219B1 (fr) Composés de co-agonistes du glucagon et du glp-1
EP3380025A4 (fr) Procédés, systèmes et dispositifs pour réparer des pathologies d'articulations anatomiques
EP3645502A4 (fr) Procédé pour la séparation d'acides aminés et de diacides à longue chaîne
EP3265477A4 (fr) Protéines de fusion à protéine de signalisation double (dsp) et procédés d'utilisation associés pour le traitement de maladies
EP3523281A4 (fr) Activateurs de flux autophagique et de phospholipase d et clairance d'agrégats de protéines comprenant tau et traitement de protéinopathies
EP3305316A4 (fr) Composition pharmaceutique pour le traitement de la sarcopénie comprenant un agoniste du récepteur du peptide-1 similaire au glucagon
MA51907A (fr) Posologie pour un traitement avec des protéines de fusion il-22 fc
MA46863A (fr) Administration intrathécale de virus adéno-associé recombinant codant pour la protéine 2 de liaison méthyl-cpg
EP3859332A4 (fr) Procédé de dosage d'hémoglobine glyquée (%)
EP3513728A4 (fr) Dispositif d'assistance au traitement de l'insomnie et programme d'assistance au traitement de l'insomnie
EP3322720A4 (fr) Procédés pour l'identification, l'évaluation, la prévention et le traitement de troubles métaboliques à l'aide de slit2
EP3337475A4 (fr) Agents de liaison à l'amyloïde contenant du nitroxyde utilisés en imagerie et à des fins thérapeutiques
EP3624785A4 (fr) Procédés de modification du traitement d'une protéine dans le réticulum endoplasmique
EP3500300A4 (fr) Composition immunosuppressante destinée à être utilisée dans le traitement de troubles immunologiques